Debra Taylor, NP
Women's Health · Greenwood, INNPI 1497853386
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,455 of the $32,907 with a category attached, or 83.4%. Organon accounts for 68.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2021 at $14,319 and has fallen 88.0% since, to $1,721 in 2025. Among women's health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $114.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$22K
- Merck$5K
- Novo Nordisk$1K
- AstraZeneca$1K
- Lilly USA, LLC$788
- AbbVie$723
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$27,45583%
- Travel & lodging$2731%
- Food & beverage$5,17916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 26 | $22,415 |
| Merck | 11 | $5,367 |
| Novo Nordisk | 63 | $1,109 |
| AstraZeneca | 28 | $1,083 |
| Lilly USA, LLC | 43 | $788 |
| AbbVie | 42 | $723 |
| Ironshore Pharmaceuticals Inc. | 7 | $143 |
| Boehringer Ingelheim | 5 | $140 |
| Pfizer | 8 | $137 |
| Axsome Therapeutics, Inc. | 7 | $130 |
| Astellas Pharma US Inc | 5 | $113 |
| GSK | 6 | $98 |
| Stryker | 3 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Mayne Pharma Commercial LLC | 5 | $60 |
| Exact Sciences | 3 | $56 |
| Corium, LLC | 4 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Abbott | 2 | $39 |
| Medtronic | 2 | $32 |
| Dynavax Technologies Corporation | 2 | $28 |
| Sobi, Inc | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Amgen | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,907 in reported general payments places this provider in the 95th percentile of 142 women's health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,753 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $951 |
| Atorvastatin Calcium | 52 | $559 |
| Famotidine | 11 | $466 |
| Pregabalin | 16 | $461 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $372 |
| Fluticasone Propionate | 14 | $249 |
| Omeprazole | 27 | $229 |
| Losartan Potassium | 20 | $214 |
| Alendronate Sodium | 15 | $179 |
| Trazodone Hcl | 13 | $176 |
| Gabapentin | 32 | $167 |
| Lisinopril | 16 | $142 |
| Amlodipine Besylate | 37 | $138 |
| Levothyroxine Sodium | 25 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $98 | $8,75311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 women's health providers in Indiana.
Other women's health in Greenwood
- Angela MorrisGreenwood$2K
- Tracy HammondGreenwood$1K
- Cara RaunickIndianapolis$73K
- Elizabeth FourmanNotre Dame$15K
- Amanda NakashianDyer$8K
- Courtney CortezIndianapolis$5K
- Natasha StruewingGreensburg$5K
- Rebecca PapamihalakisMunster$4K
- Kesha KellyIndianapolis$4K
- Amanda PhelpsEvansville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.